Emerging Drug Developer: LEAD Therapeutics

Emerging Drug Developer: LEAD Therapeutics

For up-start LEAD Therapeutics, the business plan is written right into the name. But behind the catchy acronym in play you'll find a group of experienced chemists and biotech executives with some interesting ideas about structuring a new kind of drug discovery company that can build on a low-cost equation in China while exploiting new trends in the pharma business. Their experience offers some insights into capturing the attention of venture capitalists. Article

Want more on emerging drug developers? Check out our archives.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.